Jul 07, 2025
Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)
Apr 01, 2025
Orsini Selected as the Exclusive Specialty Pharmacy for Cell Therapy ENCELTO(TM)
Jan 14, 2025
Orsini the Exclusive Specialty Pharmacy Provider for Gene Therapy KEBILIDI(TM) (eladocagene exuparvovec-tneq)
Jan 07, 2025
Orsini and PicnicHealth Partner to Improve Rare Disease Patient Care and Real-World Study Execution
Nov 25, 2024
Orsini Chosen by BridgeBio as a Specialty Pharmacy Provider for ATTRUBY(TM) (acoramidis), for the Treatment of Cardiomyopathy of Transthyretin-Mediated Amyloidosis
Nov 14, 2024
Orsini Now Distributing CASGEVY® (exagamglogene autotemcel), a Gene-Editing Therapy
Nov 05, 2024
Orsini Now a Specialty Pharmacy Provider for SAJAZIR(TM) (icatibant) Injection, to Treat Acute HAE Attacks
Oct 21, 2024
Orsini Is Now a Specialty Pharmacy Provider for FUROSCIX® (furosemide injection), an Infused Diuretic for Congestive Heart Failure
Oct 03, 2024
Orsini Launches ORBIT(TM) (Orsini Rare Business Intelligence Technology) to Enhance Rare Disease Patient Care
Sep 24, 2024
Orsini Chosen as the Exclusive Specialty Pharmacy Provider for MIPLYFFA(TM) (arimoclomol), the First FDA-Approved Treatment for Niemann-Pick Disease Type C
Aug 15, 2024
Orsini Now Dispensing Livdelzi (seladelpar), for Treatment of Rare Liver Disease
Jun 18, 2024
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders